Reflow Medical said it has completed enrollment of its Wing-IT IDE. The San Clemente-based company’s study is evaluating the ability of the Wingman Catheter to cross chronic total occlusions in peripheral lesions after failed guidewire attempts.

Eighty-five patients with advanced peripheral artery disease enrolled in the Wing-IT trial were evaluated at 12 centers in the U.S., Germany, and Austria. John R. Laird, MD, of Adventist Heart and Vascular Institute, St. Helena, California, is the principal investigator for the study.

The Wingman Crossing Catheter uses an extendable beveled tip that creates a channel to help penetrate, or cross, the occlusion. This enables further treatment of the lesion with therapeutic devices.

In a release, Isa Rizk, CEO of Reflow Medical, said, “our goal is to expand the physician’s ability to treat CTOs, which often develop in patients with advanced peripheral artery disease. Facilitating CTO crossings helps physicians avoid amputations or bypass surgery, which directly correlates to better long-term outcomes.”